Skopos Bio raises $12m for cancer-targeting radioactive therapy
Skopos Bio raised $12 million to develop cancer treatment using radioactive particles.
Melbourne-based Skopos Bio, spun out from the Peter MacCallum Cancer Centre, is developing radioactive particles that target cancer cells and limit damage to healthy tissue. The seed round was led by investors including Andrew Forrest's Tenmile, Steve Jobs' son Reed Jobs through Yosemite, and venture firm Tin Alley.
The startup was founded by three researchers: Professor Michael Hofman, who pioneered a combined imaging and radiation approach for prostate cancer, plus Associate Professors Mohammad Haskali and Luc Furic.
Skopos aims to broaden treatment beyond prostate cancer. The radiopharmaceutical approach lets doctors deliver radiation to hard-to-reach tumours while reducing damage to nearby healthy cells.
- $12 million
- Seed round funding
- 2024
- Year founded
- Hofman, Haskali, Furic
- Lead founders
- Melbourne
- Location
Why it mattersRadiopharmaceuticals could expand cancer treatment options for patients whose tumours are resistant to conventional drugs, with trials potentially beginning within years.
AustraliaAustralian cancer patients may gain access to new treatment options developed locally. The startup also signals Australia's growing precision medicine sector attracting top-tier global investors.
✓ Claims checked against the source and corrected before publish. checked 1 h ago
Open this story in InSnip →
